Tests For Neuropathy
When a doctor wants to confirm the diagnosis of neuropathy he will either arrange for the patient to be seen by a neurologist and/or request an EMG test. In the EMG laboratory neuropathy is tested for by applying small electrical shocks to the nerves and recording the activity from muscles or from the same nerve some distance away. Sometimes this test is accompanied by a fine needle being inserted in one or more muscles.
What Can Be Done About Neuropathy?
Diabetic neuropathy should be evaluated to exclude CIDP.If the patient has a high protein level in the spinal fluid. The EMG/NCV shows a neuropathy and the condition is progressive. Then they may have CIDP.
CIDP is treated by IVIg. Please read the IVIg page. IVIg will even get rid of the burning type of pain, the numbness and help improve strength. Patients have even noted that they needed less Insulin AFTER they started to use IVIg. Recommended dose of IVIg is 2g/kg per month in divided doses.Other ways to treat diabetic neuropathy is to use a exercise bicycle pedals as seen in our link pages.
Regular exercise will help control a lot of symptoms.
Contact us for any help you need in getting treatment.
You can get better too! Act fast get the treatment that can HELP YOU.
Below is a study done which documents what we are talking about:
Diabetic Neuropathy and demyelinating polyneuropathy successfully treated with intravenous immunoglobulin
Intravenous immunoglobulin successfully treated patients with diabetes-related chronic inflammatory demyelinating polyneuropathy (DM-CIDP), according to authors of a report in the Archives of Neurology.
Evidence is growing that diabetes-associated CIDP shares many features with idiopathic CIDP. One of the standard therapies for idiopathic CIDP is intravenous immunoglobulin (IVIg). Therefore, K.R. Sharma and colleagues at the University of Miami School of Medicine treated DM-CIDP patients with IVIg to determine its efficacy.
In this prospective nonblinded trial, 25 patients, age 40 to 80 years (average 64 years), with type 2 diabetes and neuropathy that met the diagnostic criteria for CIDP, and 1 patient without diabetes, received daily IVIg (400 mg/kg body weight) for 5 days. A Neuropathy Impairment Score was obtained for each patient at baseline and again 4 weeks after the start of therapy.
Patients who experienced conduction block were significantly more likely to show an improvement in Neuropathy Impairment Score: all 11 of the 11 patients who experienced conduction block showed an improvement the score, while only 10 of the 15 patients who did not have conduction block demonstrated improvement (p=0.03).
Treatment side effects were relatively minor and included reversible kidney dysfunction (3 cases), flu symptoms (5 cases), headache (5 cases), and chest pain with shortness of breath (1 case).
Sharma and colleagues concluded, "Although IVIg therapy seemed to improve DM-CIDP in this uncontrolled trial, a controlled trial is required for confirmation of our findings."
The corresponding author for this study is K.R. Sharma, University of Miami School of Medicine M740, Department of Neurology,
Key points reported in this study include:
* Patients with diabetes-associated chronic inflammatory demyelinating polyneuropathy (DM-CIDP) improved significantly after treatment with intravenous immunoglobulin (IVIg)
* Improvement in Neuropathy Impairment Score was significantly more likely for patients who experienced conduction block
We have seen patients go from wheelchair to walking with